Adverse events in nuclear medicine - Cause for concern?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 5, 2012, Pages 782-785

  Hesse, B ^a   Vinberg, N ^b   Berthelsen, A K ^a   Ballinger, J R ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region Pharmacy   (Denmark)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ERBIUM 169; GADOLINIUM CHELATE; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; LEXIDRONAM SAMARIUM SM 153; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SOMATOSTATIN RECEPTOR; STRONTIUM 89; TOSITUMOMAB I 131; YTTRIUM 90;

ADVERSE OUTCOME; BONE MARROW SUPPRESSION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; KIDNEY FUNCTION; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID DISEASE; UNSPECIFIED SIDE EFFECT;

CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862530385     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2071-6     Document Type: Editorial

References (20)

1. Hesslewood SR. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000. Eur J Nucl Med Mol Imaging. 2002;29:BP13-9.
2. Hesslewood SR, Keeling DG, Radiopharmacy Committee of European Association of Nuclear Medicine. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24:1179-82.
3. Silberstein EB, Ryan J, Pharmacopoeia Committee of the Society of Nuclear Medicine. Prevalence of adverse reactions in nuclear medicine. J NucI Med. 1996;37:185-92.
4. Kusakabe K, Okamura T, Kasagi K, Komatani A, Sato Y, Matsuda H, Maruno H; Subcommittee for Safety Issues of Radiopharmaceuticals, Medical Science, and Pharmaceutical Committee, Japan Radioisotope Association. The 27th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 30th survey in 2004). Kaku Igaku. 2006;43:23-5.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-5.
6. Santos-Oliveira R. Undesirable events with radiopharmaceuticals. Tohoku J Exp Med. 2009;217:251-7.
7. World Health Organization. Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Geneva: World Health Organization; 2002. http://whqlibdoc.who.int/hq/2002/WHO-EDM-QSM-2002.2.pdf. Accessed 29 Jan 2012.
8. Simons FER. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol. 2009;124:625-36.
9. Silberstein EB. Positron-emitting radiopharmaceuticals: how safe are they? Cancer Biother Radiopharm. 2001;16:13-5.
10. European Society of Urogenital Radiology. ESUR guidelines on contrast media, version 7.0. Vienna: European Society of Urogenital Radiology; 2008. http://www.esur.org/Contrast-media.51.0.html. Accessed 29 Jan 2012.
11. Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol. 1991;157:1153-61.
12. American College of Radiology. ACR manual on contrast media, version 7. Reston, VA: American College of Radiology; 2010. http://http://www.acr.org/ SecondaryMainMenuCategories/quality-safety/contrast-manual/FullManual.aspx.
13. Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44:519-26.
14. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33-40.
15. Roqué I, Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD003347. doi: 10.1002/14651858. CD003347.pub2.
16. European Association of Nuclear Medicine. EANM procedure guidelines for radiosynovectomy. Vienna: European Association of Nuclear Medicine; 2002. http://www.eanm.org/publications/guidelines/gl-radio-synovectomy.pdf. Accessed 29 Jan 2012.
17. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21:111-29.
18. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med. 2005;46:83S-91S.
19. Rolleman EJ, Melis M, Bernard BF, Valkema R, Boerman OC, Krenning EP. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1018-31.
20. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-70.